Since 1963, the Taisho Pharmaceutical Group has entered overseas markets through the sale of the Lipovitan series of energy drinks. Today, the Group has overseas subsidiaries in Hong Kong, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, China, and the U.S. The Group also has local production bases in Taiwan, Malaysia, the Philippines, Vietnam, and Shanghai, China.
Besides the energy drinks business, the Group is also expanding the OTC pharmaceuticals business in regions where future economic growth is anticipated. Leveraging the strong business platform it acquired in 2009, the Group is expanding business primarily in Indonesia, Thailand, Malaysia, and the Philippines. The Group has taken a number of steps to actively drive overseas business expansion. Notably, in 2011, we acquired all of the shares of Hoepharma Holdings Sdn. Bhd. of Malaysia. In 2012, we acquired all of the shares of a Mexican pharmaceutical company group (four companies including Compaņia Internacional de Comercio, S.A.P.I. de C.V. (CICSA)). Moreover, in 2014 we acquired the sales rights for the anti-inflammatory analgesic brand Flanax in the Philippines.